<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276222</url>
  </required_header>
  <id_info>
    <org_study_id>SUN101-303</org_study_id>
    <nct_id>NCT02276222</nct_id>
  </id_info>
  <brief_title>A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD</brief_title>
  <acronym>GOLDEN-5</acronym>
  <official_title>A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion Respiratory Development Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion Respiratory Development Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term safety trial of 48 weeks. Eligible subjects will enter the 48-week,
      open-label treatment period to receive one of two treatments (SUN-101 given as 50 mcg twice a
      day or Spiriva® [tiotropium] given as 18 mcg once a day).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, open-label, active-controlled, parallel-group, multicenter,
      long-term safety trial of 48 weeks of treatment with nebulized SUN-101 using an
      Investigational eFlow® Closed System (CS) nebulizer or Spiriva in approximately 1050 subjects
      with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for
      Chronic Obstructive Lung Disease (GOLD 2014) guidelines.

      Eligible subjects will enter the 48-week, open-label treatment period following randomization
      to receive one of two treatments (SUN-101 given as 50 mcg BID or Spiriva® [tiotropium] given
      as 18 mcg QD).

      The hypothesis for this study is that the incidence of treatment-emergent adverse events
      reported over the course of 48 weeks of treatment by subjects randomized to SUN-101 is
      numerically similar to the incidence of treatment-emergent adverse events reported over the
      course of 48 weeks of treatment by subject randomized to Spiriva (tiotropium).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Treatment-emergent Adverse Events</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Treatment-emergent Serious Adverse Events (SAE)</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>A treatment emergent serious adverse event (SAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Treatment-emergent Serious Adverse</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>A treatment emergent serious adverse event (SAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Discontinue the Study Due to TEAE</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Who Discontinue the Study Due to TEAE</measure>
    <time_frame>Up to 48 Weeks</time_frame>
    <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs &quot;myocardial infarction&quot;, &quot;other ischemic heart disease&quot;, &quot;central nervous system hemorrhages and cerebrovascular conditions&quot;) were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke</measure>
    <time_frame>Up to 48 Weeks</time_frame>
    <description>All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs &quot;myocardial infarction&quot;, &quot;other ischemic heart disease&quot;, &quot;central nervous system hemorrhages and cerebrovascular conditions&quot;) were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate Per 1000 Person Years of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke</measure>
    <time_frame>up to week 48</time_frame>
    <description>All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs &quot;myocardial infarction&quot;, &quot;other ischemic heart disease&quot;, &quot;central nervous system hemorrhages and cerebrovascular conditions&quot;) were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over 48 Weeks in Trough FEV1 for All Subjects</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the average of the FEV1 values collected at the end of the dosing interval at each clinic visit. The mean change from baseline in trough FEV1 over the 48 week treatment period is calculated by averaging the trough FEV1 changes from baseline across all study visits while subjects are taking randomized treatment.
Values affected by other medication use were to be set to missing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1087</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>SUN-101 50 mcg BID eFlow (CS) nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva 18 mcg QD Handihaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUN-101 50 mcg BID eFlow (CS) nebulizer</intervention_name>
    <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
    <arm_group_label>SUN-101 50 mcg BID eFlow (CS) nebulizer</arm_group_label>
    <other_name>Glycopyrrolate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spiriva® 18 mcg QD Handihaler</intervention_name>
    <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
    <arm_group_label>Spiriva 18 mcg QD Handihaler</arm_group_label>
    <other_name>(tiotropium)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients age ≥ 40 years, inclusive.

          2. A clinical diagnosis of COPD according to the GOLD 2014 guidelines.

          3. Current smokers or ex-smokers with at least 10 pack-year smoking history (eg, at least
             1 pack/day for 10 years, or equivalent).

          4. Post-bronchodilator (following inhalation of ipratropium bromide) FEV1 &lt; 80% of
             predicted normal and &gt; 0.7 L during Screening (Visit 1).

          5. Post-bronchodilator (following inhalation of ipratropium bromide) FEV1/FVC ratio &lt;
             0.70 during Screening (Visit 1).

          6. Ability to perform reproducible spirometry according to the American Thoracic Society
             (ATS) and European Respiratory Society (ERS) guidelines (2005).

          7. Subject, if female ≤ 65 years of age and of child bearing potential, must have a
             negative serum pregnancy test at Visit 1. Females of childbearing potential must be
             instructed to and agree to avoid pregnancy during the study and must use an acceptable
             method of birth control: a) an oral contraceptive, an intrauterine device (IUD),
             implantable contraceptive, transdermal or injectable contraceptive for at least 1
             month prior to entering the study with continued use throughout the study and for
             thirty days following participation; b) barrier method of contraception, e.g., condom
             and /or diaphragm with spermicide while participating in the study; and/or c)
             abstinence..

          8. Willing and able to provide written informed consent.

          9. Willing and able to attend all study visits and adhere to all study assessments and
             procedures.

        Exclusion Criteria:

          1. Severe comorbidities including unstable cardiac or pulmonary disease or any other
             medical conditions that would, in the opinion of the Investigator, preclude the
             subject from safely completing the required tests or the study, or is likely to result
             in disease progression that would require withdrawal of the subject.

          2. Concomitant clinically significant respiratory disease other than COPD (eg, asthma,
             tuberculosis, bronchiectasis or other non-specific pulmonary disease).

          3. Recent history of COPD exacerbation requiring hospitalization or need for increased
             treatments for COPD within 6 weeks prior to Screening (Visit 1).

          4. Use of daily oxygen therapy &gt; 12 hours per day.

          5. Respiratory tract infection within 6 weeks prior to Screening (Visit 1).

          6. Use of systemic steroids within 3 months prior to Screening (Visit 1).

          7. History of malignancy of any organ system, treated or untreated within the past 5
             years, with the exception of localized basal cell carcinoma of the skin.

          8. Prolonged QTc (&gt; 450 msec for males and &gt; 470 msec for females) during Screening
             (Visit 1), or history of long QT syndrome.

          9. History of or clinically significant ongoing bladder outflow obstruction or history of
             catheterization for relief of bladder outflow obstruction within the previous 6
             months.

         10. History of narrow angle glaucoma.

         11. History of hypersensitivity or intolerance to aerosol medications.

         12. Recent documented history (within the previous 3 months) of substance abuse.

         13. Significant psychiatric disease that would likely result in the subject not being able
             to complete the study, in the opinion of the Investigator.

         14. Participation in another investigational drug study where drug was received within 30
             days prior to Screening (Visit 1) or current participation in another investigational
             drug trial, including a SUN-101 study.

         15. Previously received SUN-101 (active treatment; formerly known as EP-101).

         16. Contraindicated for treatment with, or having a history of reactions/ hypersensitivity
             to anticholinergic agents, beta2 agonists, or sympathomimetic amines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Respiratory Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion Respiratory Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SEC Lung LLC</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasper Summit Research LLC</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.lEast Valley Family Physicians, PLC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Sun Clinical Research LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allianz Research Institute, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center of Fresno, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Medical Group, lnc.</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Institute For Respiratory Diseases, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Research Group, Inc</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Healthcare Assessments Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterbury Pulmonary Associates, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Clinical Research Center</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, llC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Community Research of South Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AppleMed Research, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of South Florida, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Florida, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Institute For Clinical Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ribo Research, LLC dba Peninsula Research, Inc.</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vero Lung Center</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Biomedical Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.C. Research LLC</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Premier Healthcare Research LLC</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Center of Chicago SC</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LaPorte County Institute For Clinical Research</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buynak Clinical Research, P.C.</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abraham Research, PLLC</name>
      <address>
        <city>Fort Mitchell</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Lung Clinics, PSC</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bendel Medical Research Center, LLC</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard County Center for Lung and Sleep Medicine, LLC</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Critical Care Associates of Baltimore</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cadillac Clinical Research LLC</name>
      <address>
        <city>Cadillac</city>
        <state>Michigan</state>
        <zip>49601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Research Institute of Southeast Michigan</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Chest Consultants PC</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somnos Laboratories, Inc d/b/a Somnos Clinical Research</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage Inc</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Clinical Research, LLC</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Research Center, LLC</name>
      <address>
        <city>Ocean City</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Allergy Associates, PA</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISA Clinical Research</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Research, Inc.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARSM Research</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Lake Norman</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research, LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVA Researcb</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington Davis Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunstone Medical Research, L.LC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowcountry Lung and Critical Care, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Easley Clinical Research</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Medical Research Associates</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaffney Pharmaceutical Research</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Medical Research, LLC</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Pharmaceutical Research, Inc.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Pharmaceutical Research, Inc.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeGarmo Institute of Medical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Charleston</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Carolina Pharmaceutical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CU Pharmaceutical Research</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Phase Clinical Research &amp; Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corsicana Medical Research, PLLC</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Clinical Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Consultants PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicentrum Beroun s.r o.</name>
      <address>
        <city>Beroun</city>
        <zip>266 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediTrial, s.r.o Internf a pneumoloqicka ambulance</name>
      <address>
        <city>Jindřichův Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Kyjov, p.o.</name>
      <address>
        <city>Kyjov</city>
        <zip>69733</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plicni ambulance</name>
      <address>
        <city>Neratovice</city>
        <zip>277 11</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MephaCentrum, a s Plicni oddeleni</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>708 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MephaCentrum, a.s.</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PNEUMa-HOST s LO.</name>
      <address>
        <city>Praha</city>
        <zip>158 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PLiCNI AMBULANCE ROKYCANY, s.r o.</name>
      <address>
        <city>Rokycany</city>
        <zip>337 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hrudnf ambulance s.r.o.</name>
      <address>
        <city>Zatec</city>
        <zip>438 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Kenessey Albert Korhaz-Rendetointezet, TOd6gy6gyaszati</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>H-2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csornai Margit Korhaz, TOd6gy6gyaszat</name>
      <address>
        <city>Csorna</city>
        <zip>H-9300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy Gyula Korhaz es Rendelomtezet, Klinikai Farmakologiai</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veszprern Megyei Tudbgyogyintezet</name>
      <address>
        <city>Farkasgyepű</city>
        <zip>H-8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi M6r Oktat6 Korhaz, Tudoqondozo</name>
      <address>
        <city>Kaposvar</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lumniczer Sandor Korhaz as Rendelointezet, Tudoqondozo</name>
      <address>
        <city>Kapuvar</city>
        <zip>H-9330</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Selye Janos Korhaz es Rendelointezet, Tud6gy6gyaszati Szakrendeles</name>
      <address>
        <city>Komárom</city>
        <zip>H-2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szakorvosi Rendelointezet Monor, Tudoqondozo</name>
      <address>
        <city>Monor</city>
        <zip>H-2200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revamed Eqeszsequqyi Szolqaltato Kft.</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>H-4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Si6fok Kornaz-Rendelointezet, Tudoqondozo</name>
      <address>
        <city>Siofok</city>
        <zip>H-8600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmakontroll Egeszsegugyi Szolqaltato Bt</name>
      <address>
        <city>Szazhalombatta</city>
        <zip>H-2440</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csonqrad Megyei Mellkasi Beteqseqek Szakkorhaza, Tudoqondozo lntezet</name>
      <address>
        <city>Szeged</city>
        <zip>H-6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Territorial SBI of Healthcare &lt;Territorial Clinical Hospital&gt;</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI Far Eastern Research Centre ofPhysiology and Pathology of Breathing of Siberian branch of RAMS</name>
      <address>
        <city>Blagoveshchensk</city>
        <zip>675000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBI of Healthcare Regional Clinical Hospital #4 City consultative department for pulmonological patientsr</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Autonomous Institution (City ClinicalHospital #14)</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Budget Institution of Healthcare (City Clinical Hospital #3 n.a. M.A. Podgorbunsky)</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000,</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSSI Scientific Research Institute of Complex Cardiovascular Pathology</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Private Institution of Healthcare &lt;Scientific Clinical Center&gt;</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBI of Healthcare of Nizhny-Novgorod region</name>
      <address>
        <city>Nizhny-Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SB1 of Healthcare of Novosibirsk region &lt;Novosibirsk State Regional Clinical Hospital&gt;l</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBI of Healthcare of Novosibirsk region &lt;Novosibirsk State Regional Clinical Hospital&gt;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI of HPE &lt;North-West State Medical University n.a. LL Mechnikov&gt;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Biomedical, Russian Group LLC</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194358</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBr of Helathcareof Yaraslavl region Clinical Hospital of Emervency care n.a.N.V. Solovyev</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <results_reference>
    <citation>Ferguson GT, Goodin T, Tosiello R, Wheeler A, Kerwin E. Long-term safety of glycopyrrolate/eFlow(®) CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respir Med. 2017 Nov;132:251-260. doi: 10.1016/j.rmed.2017.08.020. Epub 2017 Aug 24.</citation>
    <PMID>28919143</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <results_first_submitted>January 2, 2018</results_first_submitted>
  <results_first_submitted_qc>February 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2018</results_first_posted>
  <disposition_first_submitted>March 18, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 18, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 15, 2016</disposition_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
          <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
        </group>
        <group group_id="P2">
          <title>Spiriva 18 mcg QD Handihaler</title>
          <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="621"/>
                <participants group_id="P2" count="466"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="436">one subject withdrew at randomization due to a pre-treatment event prior to being dosed</participants>
                <participants group_id="P2" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non compliance with study medication</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>sheduling conflict</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject withdrew after randomization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>As noted in the participant flow section, one subject withdrew at randomization due to a pre-treatment event prior to being dosed bringing the population total to 1086 from 1087.</population>
      <group_list>
        <group group_id="B1">
          <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
          <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
        </group>
        <group group_id="B2">
          <title>Spiriva 18 mcg QD Handihaler</title>
          <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="620"/>
            <count group_id="B2" value="466"/>
            <count group_id="B3" value="1086"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="586"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="8.46"/>
                    <measurement group_id="B2" value="63.3" spread="8.97"/>
                    <measurement group_id="B3" value="63.3" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="476"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="611"/>
                    <measurement group_id="B2" value="457"/>
                    <measurement group_id="B3" value="1068"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="582"/>
                    <measurement group_id="B2" value="436"/>
                    <measurement group_id="B3" value="1018"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="556"/>
                    <measurement group_id="B2" value="421"/>
                    <measurement group_id="B3" value="977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>cardiovascular risk (low/high) and categories for high cardiovascular risk</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>low cardiovascular risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high cardiovascular risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="401"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ischemic heart disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cerebrovascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>periheral arterial disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>clinically significant arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hyertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>background long-acting beta (2) agonist (LABA) use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>background LABA use -yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>background LABA use -no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="353"/>
                    <measurement group_id="B2" value="274"/>
                    <measurement group_id="B3" value="627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume in one second (FEV1)</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3399" spread="0.49604"/>
                    <measurement group_id="B2" value="1.3257" spread="0.50186"/>
                    <measurement group_id="B3" value="1.3365" spread="0.51414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Treatment-emergent Adverse Events (TEAE)</title>
        <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent Adverse Events (TEAE)</title>
          <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430"/>
                    <measurement group_id="O2" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Treatment-emergent Adverse Events</title>
        <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Treatment-emergent Adverse Events</title>
          <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4"/>
                    <measurement group_id="O2" value="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Treatment-emergent Serious Adverse Events (SAE)</title>
        <description>A treatment emergent serious adverse event (SAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent Serious Adverse Events (SAE)</title>
          <description>A treatment emergent serious adverse event (SAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Treatment-emergent Serious Adverse</title>
        <description>A treatment emergent serious adverse event (SAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Treatment-emergent Serious Adverse</title>
          <description>A treatment emergent serious adverse event (SAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Discontinue the Study Due to TEAE</title>
        <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Discontinue the Study Due to TEAE</title>
          <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Discontinue the Study Due to TEAE</title>
        <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
        <time_frame>Up to 48 Weeks</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Discontinue the Study Due to TEAE</title>
          <description>A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke</title>
        <description>All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs “myocardial infarction”, “other ischemic heart disease”, “central nervous system hemorrhages and cerebrovascular conditions”) were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke</title>
          <description>All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs “myocardial infarction”, “other ischemic heart disease”, “central nervous system hemorrhages and cerebrovascular conditions”) were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACE score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cardiovascular death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-fatal myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-fatal stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke</title>
        <description>All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs “myocardial infarction”, “other ischemic heart disease”, “central nervous system hemorrhages and cerebrovascular conditions”) were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact.</description>
        <time_frame>Up to 48 Weeks</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke</title>
          <description>All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs “myocardial infarction”, “other ischemic heart disease”, “central nervous system hemorrhages and cerebrovascular conditions”) were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACE score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cardiovascular death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-fatal myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-fatal stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate Per 1000 Person Years of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke</title>
        <description>All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs “myocardial infarction”, “other ischemic heart disease”, “central nervous system hemorrhages and cerebrovascular conditions”) were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact.</description>
        <time_frame>up to week 48</time_frame>
        <population>Incidence rate: TT= Total Time in years. Total Time (TT) is defined as the time from the first date of study drug until the latter of the date of last contact or 30 days after the date of last dose. Incidence Rate (per 1000 person-years) = n/TT x 1000.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate Per 1000 Person Years of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke</title>
          <description>All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs “myocardial infarction”, “other ischemic heart disease”, “central nervous system hemorrhages and cerebrovascular conditions”) were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact.</description>
          <population>Incidence rate: TT= Total Time in years. Total Time (TT) is defined as the time from the first date of study drug until the latter of the date of last contact or 30 days after the date of last dose. Incidence Rate (per 1000 person-years) = n/TT x 1000.</population>
          <units>event per 1000 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACE score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cardiovascular death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-fatal myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-fatal stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over 48 Weeks in Trough FEV1 for All Subjects</title>
        <description>Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the average of the FEV1 values collected at the end of the dosing interval at each clinic visit. The mean change from baseline in trough FEV1 over the 48 week treatment period is calculated by averaging the trough FEV1 changes from baseline across all study visits while subjects are taking randomized treatment.
Values affected by other medication use were to be set to missing.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>Intent to Treat (ITT) Population: all subjects who were randomized to treatment and received at least one dose of study medication. Subjects were analyzed based on the treatment they were randomized to.</population>
        <group_list>
          <group group_id="O1">
            <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
            <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Spiriva 18 mcg QD Handihaler</title>
            <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline Over 48 Weeks in Trough FEV1 for All Subjects</title>
          <description>Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the average of the FEV1 values collected at the end of the dosing interval at each clinic visit. The mean change from baseline in trough FEV1 over the 48 week treatment period is calculated by averaging the trough FEV1 changes from baseline across all study visits while subjects are taking randomized treatment.
Values affected by other medication use were to be set to missing.</description>
          <population>Intent to Treat (ITT) Population: all subjects who were randomized to treatment and received at least one dose of study medication. Subjects were analyzed based on the treatment they were randomized to.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1016" spread="0.00698"/>
                    <measurement group_id="O2" value="0.0931" spread="0.00779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4041</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean (SE)</param_type>
            <param_value>0.0084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0114</ci_lower_limit>
            <ci_upper_limit>0.0283</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to week 48</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SUN-101 50 mcg BID eFlow (CS) Nebulizer</title>
          <description>SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
SUN-101 50 mcg BID eFlow (CS) nebulizer: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer</description>
        </group>
        <group group_id="E2">
          <title>Spiriva 18 mcg QD Handihaler</title>
          <description>Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Spiriva® 18 mcg QD Handihaler: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="620"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="620"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>arterial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>cardio respiratory arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>myocardial infraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>verntricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>duodenal ulcer, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>generalized oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>choleithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>gastronenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pheumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="620"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>systemic candida</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>impacted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pubis fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>joint effsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>benign lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>carcinoid tumor of the apendix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>endometrial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>non-hodgkins lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pancreatic crcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>hashimoto's encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>multile sclerosis relapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>serotonin syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>renal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="620"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>pluritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>aortic aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>arterios clerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="620"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="620"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="42" subjects_affected="38" subjects_at_risk="620"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="119" subjects_affected="91" subjects_at_risk="620"/>
                <counts group_id="E2" events="107" subjects_affected="82" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="78" subjects_affected="73" subjects_at_risk="620"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the Study is part of a multi-center study , the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion Pharmaceuticals Inc.</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

